Volume 26, Number 8—August 2020
Linezolid-Associated Neurologic Adverse Events in Patients with Multidrug-Resistant Tuberculosis, France
|Age, y, median (IQR)
|Country or region of origin|
|Other Eastern Europe and Russia||8 (14)|
|History of treated TB||37 (65)|
|History of isoniazid-based regimen||23 (40)|
|History of linezolid-based regimen
|HIV infection||5 (9)|
|Hepatitis B surface antigen–positive||1 (2)|
|Hepatitis C||24 (42)|
|History of intravenous drug use||20 (35)|
|Opioid substitution therapy, methadone or buprenorphine||12 (21)|
|Body mass index at first visit, median (IQR), kg/m2||20.1 (17.9–22.4)|
|Albumin level at first visit, median (IQR), g/L||34 (30–38)|
*Values are no. (%) unless otherwise indicated. IQR, interquartile range; TB, tuberculosis.
†One from Algeria, 1 from Cameroon, 1 from Democratic Republic of the Congo, 2 from Côte d’Ivoire.
‡Three from China, 2 from Tibet.
Page created: June 12, 2020
Page updated: July 17, 2020
Page reviewed: July 17, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.